206A — PRISM Biolab Co Balance Sheet
0.000.00%
Last trade - 00:00- ¥10bn
- ¥6bn
- ¥306m
Annual balance sheet for PRISM Biolab Co, fiscal year end - September 30th, JPY millions except per share, conversion factor applied.
2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | Yuho |
| Standards: | JAS | JAS | JAS |
| Status: | Final | Final | Final |
| Cash and Equivalents | |||
| Cash and Short Term Investments | 1,688 | 1,134 | 4,392 |
| Net Total Accounts Receivable | |||
| Net Total Receivables | 21.7 | 40.2 | 54.9 |
| Prepaid Expenses | |||
| Total Other Current Assets | |||
| Total Current Assets | 1,732 | 1,198 | 4,483 |
| Gross Property, Plant And Equipment | |||
| Accumulated Depreciation | |||
| Net Property, Plant And Equipment | 0 | 0 | 0 |
| Other Long Term Assets | |||
| Total Assets | 1,740 | 1,211 | 4,529 |
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Current Portion of Long Term Debt / Capital Leases | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 65.1 | 63.2 | 1,020 |
| Long Term Debt | |||
| Total Long Term Debt | |||
| Total Debt | |||
| Total Other Liabilities | |||
| Total Liabilities | 65.2 | 63.4 | 1,026 |
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Other Equity | |||
| Total Equity | 1,675 | 1,148 | 3,503 |
| Total Liabilities & Shareholders' Equity | 1,740 | 1,211 | 4,529 |
| Total Common Shares Outstanding |